Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2697) 2697
Publication (234) 234
Book Chapter (64) 64
Book Review (20) 20
Dissertation (16) 16
Conference Proceeding (12) 12
Magazine Article (3) 3
Web Resource (3) 3
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hyperphosphatemia (1899) 1899
humans (1772) 1772
index medicus (1160) 1160
male (1007) 1007
urology & nephrology (987) 987
female (892) 892
middle aged (657) 657
aged (523) 523
hyperphosphatemia - etiology (443) 443
hemodialysis-patients (440) 440
calcium (438) 438
hemodialysis (435) 435
adult (430) 430
chronic kidney-disease (407) 407
hyperphosphatemia - drug therapy (400) 400
phosphorus (398) 398
phosphates - blood (391) 391
renal dialysis (373) 373
animals (371) 371
mortality (371) 371
phosphate (368) 368
chronic kidney disease (343) 343
phosphates (321) 321
sevelamer (320) 320
kidney failure, chronic - therapy (309) 309
nephrology (308) 308
kidney failure, chronic - complications (295) 295
dialysis (289) 289
calcification (288) 288
phosphorus - blood (288) 288
stage renal-disease (259) 259
vascular calcification (256) 256
treatment outcome (250) 250
hyperphosphatemia - blood (249) 249
risk factors (248) 248
phosphates - metabolism (245) 245
dialysis patients (242) 242
parathyroid-hormone (242) 242
calcium - blood (236) 236
chelating agents - therapeutic use (232) 232
secondary hyperparathyroidism (231) 231
phosphate binder (221) 221
parathyroid hormone (220) 220
parathyroid hormone - blood (216) 216
mineral metabolism (202) 202
lanthanum carbonate (201) 201
phosphate binders (199) 199
hypocalcemia (191) 191
chronic-renal-failure (189) 189
serum phosphorus (185) 185
chronic kidney failure (182) 182
kidney diseases (181) 181
hyperparathyroidism (175) 175
renal dialysis - adverse effects (171) 171
hyperphosphatemia - complications (162) 162
renal insufficiency, chronic - complications (161) 161
vitamin d (160) 160
kidney failure, chronic - blood (159) 159
disease (153) 153
time factors (150) 150
medicine & public health (148) 148
sevelamer hydrochloride (148) 148
polyamines - therapeutic use (146) 146
endocrinology & metabolism (144) 144
aged, 80 and over (141) 141
medicine, general & internal (141) 141
hypercalcemia (140) 140
rats (140) 140
coronary-artery calcification (139) 139
hyperphosphatemia - prevention & control (138) 138
pharmacology & pharmacy (137) 137
hyperphosphatemia - metabolism (136) 136
lanthanum - therapeutic use (134) 134
mortality risk (133) 133
transplantation (133) 133
calcium carbonate (130) 130
prospective studies (128) 128
metabolism (126) 126
fgf23 (124) 124
care and treatment (123) 123
hypophosphatemia (119) 119
pediatrics (119) 119
analysis (115) 115
biomarkers - blood (115) 115
phosphates - adverse effects (114) 114
retrospective studies (114) 114
administration, oral (113) 113
calcium-carbonate (113) 113
cardiovascular-disease (112) 112
child (110) 110
mice (109) 109
association (108) 108
hyperphosphatemia - diagnosis (108) 108
hematology (104) 104
hyperphosphatemia - therapy (104) 104
adolescent (103) 103
article (103) 103
calcinosis - etiology (103) 103
diet (103) 103
homeostasis (101) 101
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2380) 2380
Spanish (93) 93
German (78) 78
French (54) 54
Japanese (54) 54
Italian (19) 19
Russian (19) 19
Korean (18) 18
Polish (12) 12
Portuguese (8) 8
Chinese (7) 7
Czech (4) 4
Danish (3) 3
Turkish (3) 3
Croatian (2) 2
Estonian (1) 1
Finnish (1) 1
Hungarian (1) 1
Indonesian (1) 1
Persian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis‐Hyperphosphatemia Syndrome
by Ramnitz, Mary Scott and Gourh, Pravitt and Goldbach‐Mansky, Raphaela and Wodajo, Felasfa and Ichikawa, Shoji and Econs, Michael J and White, Kenneth E and Molinolo, Alfredo and Chen, Marcus Y and Heller, Theo and Del Rivero, Jaydira and Seo‐Mayer, Patricia and Arabshahi, Bita and Jackson, Malaka B and Hatab, Sarah and McCarthy, Edward and Guthrie, Lori C and Brillante, Beth A and Gafni, Rachel I and Collins, Michael T
Journal of Bone and Mineral Research, ISSN 0884-0431, 10/2016, Volume 31, Issue 10, pp. 1845 - 1854
ABSTRACT Familial tumoral calcinosis (FTC)/hyperostosis‐hyperphosphatemia syndrome (HHS) is a rare disorder caused by mutations in the genes encoding... 
FAMILIAL TUMORAL CALCINOSIS | HYPEROSTOSIS‐HYPERPHOSPHATEMIA SYNDROME | FIBROBLAST GROWTH FACTOR 23 | HYPERPHOSPHATEMIA | HYPEROSTOSIS-HYPERPHOSPHATEMIA SYNDROME | GALNT3 | PHOSPHATE BINDER | FIBROBLAST-GROWTH-FACTOR-23 | ACETAZOLAMIDE | HOMOZYGOUS MISSENSE MUTATION | CHILDREN | HYPOPHOSPHATEMIA | ENDOCRINOLOGY & METABOLISM | CALCIFICATION | CALCINOSIS | MANIFESTATIONS | Calcinosis - genetics | Humans | Hyperostosis, Cortical, Congenital - therapy | Fibroblast Growth Factors - genetics | Male | Hyperostosis, Cortical, Congenital - pathology | Hyperphosphatemia - pathology | Hyperphosphatemia - blood | Hyperostosis - blood | N-Acetylgalactosaminyltransferases - genetics | Adult | Female | Hyperostosis - pathology | Hyperphosphatemia - therapy | Child | Hyperostosis - genetics | Hyperostosis - therapy | Calcinosis - blood | Hyperostosis, Cortical, Congenital - genetics | Hyperostosis, Cortical, Congenital - blood | Calcinosis - therapy | Glucuronidase - genetics | Adolescent | Hyperphosphatemia - genetics | Calcinosis - pathology | Cohort Studies | Care and treatment | Phosphorus imbalance | Genetic aspects | C-reactive protein | Gene mutations | hyperostosis-hyperphosphatemia syndrome | Familial tumoral calcinosis | hyperphosphatemia | fibroblast growth factor 23
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease
by Isakova, Tamara and Wahl, Patricia and Vargas, Gabriela S and Gutiérrez, Orlando M and Scialla, Julia and Xie, Huiliang and Appleby, Dina and Nessel, Lisa and Bellovich, Keith and Chen, Jing and Hamm, Lee and Gadegbeku, Crystal and Horwitz, Edward and Townsend, Raymond R and Anderson, Cheryl A.M and Lash, James P and Hsu, Chi-yuan and Leonard, Mary B and Wolf, Myles and on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Group and CRIC Study Grp and on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Group
Kidney International, ISSN 0085-2538, 06/2011, Volume 79, Issue 12, pp. 1370 - 1378
Fibroblast growth factor 23 (FGF23) regulates phosphorus metabolism and is a strong predictor of mortality in dialysis patients. FGF23 is thought to be an... 
phosphate | FGF23 | chronic kidney disease | MORTALITY | VITAMIN-D | KLOTHO | FIBROBLAST-GROWTH-FACTOR-23 | SECONDARY HYPERPARATHYROIDISM | RENAL-DISEASE | FGF RECEPTOR | PATHOGENESIS | CALCIUM | UROLOGY & NEPHROLOGY | PHOSPHORUS-METABOLISM | Predictive Value of Tests | Up-Regulation | Biomarkers - urine | Prospective Studies | United States | Humans | Middle Aged | Hyperparathyroidism, Secondary - physiopathology | Male | Parathyroid Hormone - blood | Renal Insufficiency, Chronic - complications | Hyperparathyroidism, Secondary - urine | Hyperphosphatemia - blood | Time Factors | Phosphates - urine | Phosphates - blood | Female | Hyperphosphatemia - urine | Renal Insufficiency, Chronic - diagnosis | Severity of Illness Index | Glomerular Filtration Rate | Phosphorus, Dietary - metabolism | Biomarkers - blood | Renal Insufficiency, Chronic - physiopathology | Renal Insufficiency, Chronic - blood | Hyperparathyroidism, Secondary - blood | Hyperparathyroidism, Secondary - diagnosis | Fibroblast Growth Factors - blood | Hyperphosphatemia - etiology | Aged | Hyperparathyroidism, Secondary - etiology | Hyperphosphatemia - physiopathology | Hyperphosphatemia - diagnosis | Renal Insufficiency, Chronic - urine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Use of phosphate-binding agents is associated with a lower risk of mortality
by Cannata-Andía, Jorge B and Fernández-Martín, José L and Locatelli, Francesco and London, Gérard and Gorriz, José L and Floege, Jürgen and Ketteler, Markus and Ferreira, Aníbal and Covic, Adrian and Rutkowski, Boleslaw and Memmos, Dimitrios and Bos, Willem-Jan and Teplan, Vladimir and Nagy, Judit and Tielemans, Christian and Verbeelen, Dierik and Goldsmith, David and Kramar, Reinhard and Martin, Pierre-Yves and Wüthrich, Rudolf P and Pavlovic, Drasko and Benedik, Miha and Sánchez, José Emilio and Martínez-Camblor, Pablo and Naves-Díaz, Manuel and Carrero, Juan J and Zoccali, Carmine
Kidney International, ISSN 0085-2538, 11/2013, Volume 84, Issue 5, pp. 998 - 1008
Hyperphosphatemia has been associated with higher mortality risk in CKD 5 patients receiving dialysis. Here, we determined the association between the use of... 
dialysis | phosphate binders | mineral metabolism | hyperparathyroidism | hyperphosphatemia | mortality risk | VITAMIN-D | EUROPEAN HEMODIALYSIS POPULATION | VASCULAR CALCIFICATION | SECONDARY HYPERPARATHYROIDISM | DIALYSIS PATIENTS | CALCIUM | RENAL-FAILURE | UROLOGY & NEPHROLOGY | CHRONIC KIDNEY-DISEASE | PRACTICE PATTERNS | SEVELAMER HYDROCHLORIDE | Multivariate Analysis | Prospective Studies | Hyperphosphatemia - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Hyperphosphatemia - blood | Renal Insufficiency, Chronic - therapy | Renal Dialysis - mortality | Time Factors | Aged, 80 and over | Cardiovascular Diseases - mortality | Phosphates - blood | Renal Insufficiency, Chronic - mortality | Female | Renal Insufficiency, Chronic - diagnosis | Chelating Agents - therapeutic use | Cardiovascular Diseases - diagnosis | Risk Factors | Proportional Hazards Models | Europe - epidemiology | Treatment Outcome | Biomarkers - blood | Chi-Square Distribution | Renal Insufficiency, Chronic - blood | Propensity Score | Renal Dialysis - adverse effects | Hyperphosphatemia - drug therapy | Aged | Hyperphosphatemia - diagnosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Activation of the Nrf2‐ARE Signaling Pathway Prevents Hyperphosphatemia‐Induced Vascular Calcification by Inducing Autophagy in Renal Vascular Smooth Muscle Cells
by Yao, Li and Wang, Jian and Tian, Bin‐Yao and Xu, Tian‐Hua and Sheng, Zi‐Tong
Journal of Cellular Biochemistry, ISSN 0730-2312, 12/2017, Volume 118, Issue 12, pp. 4708 - 4715
ABSTRACT This study investigates the effect of nuclear factor erythroid 2‐related factor 2‐antioxidant response element (Nrf2‐ARE) signaling pathway in... 
AUTOPHAGY | HYPERPHOSPHATEMIA‐INDUCED VASCULAR CALCIFICATION | VASCULAR SMOOTH MUSCLE CELL | Nrf2‐ARE SIGNALING PATHWAY | Nrf2-ARE SIGNALING PATHWAY | HYPERPHOSPHATEMIA-INDUCED VASCULAR CALCIFICATION | OXIDATIVE STRESS | MANAGEMENT | INFLAMMATORY DISEASES | BIOCHEMISTRY & MOLECULAR BIOLOGY | SERUM PHOSPHORUS | RUNX2 | CELL BIOLOGY | IN-VITRO | GAMMA-GLUTAMYLCYSTEINE SYNTHETASE | HEMODIALYSIS | CHRONIC KIDNEY-DISEASE | EXPRESSION | Kidney - blood supply | Kidney - pathology | Muscle, Smooth, Vascular - metabolism | Response Elements | Signal Transduction | Myocytes, Smooth Muscle - pathology | Hyperphosphatemia - metabolism | Rats | Vascular Calcification - prevention & control | Male | Vascular Calcification - pathology | Autophagy | Rats, Sprague-Dawley | Hyperphosphatemia - pathology | Vascular Calcification - metabolism | Kidney - metabolism | Muscle, Smooth, Vascular - pathology | Animals | Hyperphosphatemia - prevention & control | NF-E2-Related Factor 2 - metabolism | Myocytes, Smooth Muscle - metabolism | Prevention | Calcification | Smooth muscle | Bone morphogenetic proteins | Phosphorus imbalance | Transmission electron microscopes | Calcification (ectopic) | Cbfa-1 protein | Ion concentration | Kidneys | Bone morphogenetic protein 2 | Calcium | Genes | Phagosomes | Phosphorus | Activation | siRNA | Western blotting | Polymerase chain reaction | Antioxidants | Signal transduction | Biomedical materials | Hyperphosphatemia | Biocompatibility | Phagocytosis | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
by Floege, Jürgen and Covic, Adrian C and Ketteler, Markus and Rastogi, Anjay and Chong, Edward M.F and Gaillard, Sylvain and Lisk, Laura J and Sprague, Stuart M and PA21 Study Grp and PA21 Study Group
Kidney International, ISSN 0085-2538, 09/2014, Volume 86, Issue 3, pp. 638 - 647
Efficacy of PA21 (sucroferric oxyhydroxide), a novel calcium-free polynuclear iron(III)-oxyhydroxide phosphate binder, was compared with that of sevelamer... 
dialysis | phosphate binder | sevelamer | hyperphosphatemia | PA21 | adherence | MORTALITY | PHOSPHORUS | PREVALENCE | DOPPS | FERRIC CITRATE | HEMODIALYSIS-PATIENTS | UROLOGY & NEPHROLOGY | CHRONIC KIDNEY-DISEASE | PRACTICE PATTERNS | STAGE RENAL-DISEASE | Nausea - chemically induced | Polyamines - adverse effects | Humans | Middle Aged | Induction Chemotherapy | Male | Polyamines - therapeutic use | Patient Dropouts | Renal Insufficiency, Chronic - complications | Diarrhea - chemically induced | Hyperphosphatemia - blood | Renal Insufficiency, Chronic - therapy | Adult | Female | Maintenance Chemotherapy | Sevelamer | Chelating Agents - therapeutic use | Chelating Agents - adverse effects | Constipation - chemically induced | Medication Adherence | Peritoneal Dialysis | Hyperphosphatemia - etiology | Phosphorus - blood | Ferric Compounds - therapeutic use | Hyperphosphatemia - drug therapy | Aged | Ferric Compounds - adverse effects | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Erratum to: Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study (Clin Exp Nephrol, 10.1007/s10157-016-1299-z)
by Koiwa, Fumihiko and Terao, Akira
Clinical and Experimental Nephrology, ISSN 1342-1751, 06/2017, Volume 21, Issue 3, pp. 523 - 523
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s10157-016-1350-0 
Hyperphosphatemia | Hemodialysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: A meta-analysis of randomized controlled trials
by Patel, Leena and Bernard, Lisa M and Elder, Grahame J
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 02/2016, Volume 11, Issue 2, pp. 232 - 244
Background and objectives People with CKD stages 3-5 and on dialysis (5D) have dramatically increased mortality, which has been associated with... 
Calcium | Randomized controlled trials as topic | Humans | Mortality | Chronic kidney disease | Hospitalization | Sevelamer | Phosphate binders | Meta-analysis | CORONARY-ARTERY CALCIFICATION | CARBONATE | CROSSOVER DESIGN | HEMODIALYSIS-PATIENTS | UROLOGY & NEPHROLOGY | OPEN-LABEL | PHOSPHATE BINDERS | CHRONIC KIDNEY-DISEASE | STAGE RENAL-DISEASE | BONE TURNOVER | HYDROCHLORIDE | Hyperphosphatemia - mortality | Risk Factors | Treatment Outcome | Biomarkers - blood | Renal Insufficiency, Chronic - complications | Chi-Square Distribution | Randomized Controlled Trials as Topic | Sevelamer - therapeutic use | Hyperphosphatemia - blood | Renal Insufficiency, Chronic - therapy | Calcium Compounds - adverse effects | Calcium Compounds - therapeutic use | Renal Dialysis - mortality | Hyperphosphatemia - etiology | Renal Dialysis - adverse effects | Phosphates - blood | Renal Insufficiency, Chronic - mortality | Hyperphosphatemia - drug therapy | Renal Insufficiency, Chronic - diagnosis | Odds Ratio | Sevelamer - adverse effects | Chelating Agents - therapeutic use | Chelating Agents - adverse effects | phosphate binders | chronic kidney disease | calcium | hospitalization | mortality | meta-analysis | sevelamer | randomized controlled trials as topic | Original | humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The challenge of controlling phosphorus in chronic kidney disease
by Cannata-Andía, Jorge B and Martin, Kevin J
Nephrology Dialysis Transplantation, ISSN 0931-0509, 04/2016, Volume 31, Issue 4, pp. 541 - 547
The pathogenesis and management of chronic kidney disease-mineral bone disorders (CKD-MBD) has experienced major changes, but the control of serum phosphorus... 
clinical management | chronic kidney disease | phosphate control | hyperphosphatemia | Renal Insufficiency, Chronic - blood | Hyperphosphatemia - blood | Hyperphosphatemia - etiology | Hyperphosphatemia - prevention & control | Phosphorus - blood | Humans | Phosphorus, Dietary - administration & dosage | Renal Insufficiency, Chronic - complications
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro
by Sage, Andrew P and Lu, Jinxiu and Tintut, Yin and Demer, Linda L
Kidney International, ISSN 0085-2538, 02/2011, Volume 79, Issue 4, pp. 414 - 422
Vascular calcification, which contributes to cardiovascular disease in patients with uremic hyperphosphatemia, is associated with vascular cell expression of... 
phosphate | gene transcription | hyperphosphatemia | osteopontin | vascular calcification | EXTRACELLULAR CALCIUM | UREMIC RATS | SERUM | POTENTIAL MECHANISM | MEDIAL CALCIFICATION | CALCIUM-PHOSPHATE CRYSTALS | ARTERIAL CALCIFICATION | UROLOGY & NEPHROLOGY | CHRONIC KIDNEY-DISEASE | FETUIN-A | Osteopontin - genetics | Nanoparticles - chemistry | Myocytes, Smooth Muscle - pathology | Hyperphosphatemia - metabolism | DNA Primers - genetics | Calcinosis - etiology | Base Sequence | Cell Differentiation | Calcinosis - metabolism | Myocytes, Smooth Muscle - drug effects | Myocytes, Smooth Muscle - metabolism | Calcium Phosphates - pharmacology | Osteogenesis - genetics | Hyperphosphatemia - complications | Bone Morphogenetic Protein 2 - genetics | Cell Line | Microscopy, Electron, Scanning | Nanoparticles - ultrastructure | Up-Regulation - drug effects | Animals | Hyperphosphatemia - genetics | Mice | Calcinosis - pathology | In Vitro Techniques | Calcium Phosphates - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis
by Yokoyama, Keitaro and Akiba, Takashi and Fukagawa, Masafumi and Nakayama, Masaaki and Sawada, Kenichi and Kumagai, Yuji and Chertow, Glenn M and Hirakata, Hideki
Nephrology Dialysis Transplantation, ISSN 0931-0509, 05/2014, Volume 29, Issue 5, pp. 1053 - 1060
Background JTT-751 is a novel phosphate binder containing ferric citrate as the active ingredient. Methods In this Phase 3, multicenter, randomized,... 
hemodialysis | Clinical trial | phosphate binder | ferric citrate | hyperphosphatemia | clinical trial | KIDNEY-DISEASE | DIALYSIS PATIENTS | CALCIUM | KDIGO | UROLOGY & NEPHROLOGY | GUIDELINE | TRANSPLANTATION | Humans | Japan | Middle Aged | Male | Polyamines - therapeutic use | Parathyroid Hormone - blood | Kidney Failure, Chronic - therapy | Young Adult | Hyperphosphatemia - etiology | Ferric Compounds - therapeutic use | Kidney Failure, Chronic - complications | Adult | Female | Hyperphosphatemia - drug therapy | Sevelamer | Chelating Agents - therapeutic use | Hyperphosphatemia - diagnosis | Renal Dialysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Prevention and treatment of hyperphosphatemia in chronic kidney disease
by Vervloet, Marc G and van Ballegooijen, Adriana J
Kidney International, ISSN 0085-2538, 05/2018, Volume 93, Issue 5, pp. 1060 - 1072
Hyperphosphatemia has consistently been shown to be associated with dismal outcome in a wide variety of populations, particularly in chronic kidney disease... 
phosphate binders | intestinal phosphate absorption | chronic kidney disease | hyperphosphatemia | dietary phosphate | SERUM PHOSPHORUS | DIETARY PHOSPHORUS RESTRICTION | ALL-CAUSE MORTALITY | CORONARY-ARTERY CALCIFICATION | DIALYSIS PATIENTS | HEMODIALYSIS-PATIENTS | CARDIOVASCULAR-DISEASE | UROLOGY & NEPHROLOGY | PARATHYROID-HORMONE | STAGE RENAL-DISEASE | Risk Reduction Behavior | Humans | Risk Factors | Phosphorus, Dietary - adverse effects | Treatment Outcome | Biomarkers - blood | Phosphorus, Dietary - blood | Renal Insufficiency, Chronic - blood | Renal Insufficiency, Chronic - epidemiology | Hyperphosphatemia - blood | Renal Insufficiency, Chronic - therapy | Animals | Hyperphosphatemia - prevention & control | Hyperphosphatemia - epidemiology | Phosphates - blood | Recommended Dietary Allowances | Hyperphosphatemia - therapy | Chelating Agents - therapeutic use | Chelating Agents - adverse effects | Intervention | Phosphates | Additives | Kidneys | Working groups | Comorbidity | Hemodialysis | Toxicity | Mortality | Clinical trials | Homeostasis | Cardiovascular disease | Studies | Nutrition research | Diet | Phosphate | Hyperphosphatemia | Fast food | Physiology | Kidney diseases | Cardiovascular diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis
by Jamal, Sophie A, Dr and Vandermeer, Ben, MSc and Raggi, Paolo, Prof and Mendelssohn, David C, Prof and Chatterley, Trish, MLIS and Dorgan, Marlene, MLS and Lok, Charmaine E, MD and Fitchett, David, MD and Tsuyuki, Ross T, Prof
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9900, pp. 1268 - 1277
Summary Background Phosphate binders (calcium-based and calcium-free) are recommended to lower serum phosphate and prevent hyperphosphataemia in patients with... 
Internal Medicine | TRIAL | SEVELAMER | PHOSPHORUS | MEDICINE, GENERAL & INTERNAL | AORTIC CALCIFICATION | IMPACT | CORONARY-ARTERY CALCIFICATION | CARBONATE | HEMODIALYSIS-PATIENTS | RENAL-DISEASE | PROGRESSION | Hyperphosphatemia - mortality | Humans | Middle Aged | Calcium Carbonate - therapeutic use | Male | Phosphates - therapeutic use | Renal Insufficiency, Chronic - complications | Cause of Death | Randomized Controlled Trials as Topic | Calcium Compounds - therapeutic use | Renal Dialysis - mortality | Hyperphosphatemia - etiology | Hyperphosphatemia - prevention & control | Renal Dialysis - adverse effects | Renal Insufficiency, Chronic - mortality | Female | Acetates - therapeutic use | Aged | Chelating Agents - therapeutic use | Research | Chronic kidney failure | Drug therapy | Patient outcomes | Diabetes | Hemodialysis | Womens health | Medical treatment | Mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights